Akili (NASDAQ:AKLI) Receives New Coverage from Analysts at Cowen

Cowen began coverage on shares of Akili (NASDAQ:AKLIGet Rating) in a report issued on Tuesday morning, The Fly reports. The firm issued an outperform rating on the stock.

Akili Price Performance

Shares of NASDAQ:AKLI opened at $4.53 on Tuesday. Akili has a 12-month low of $3.73 and a 12-month high of $37.58.

About Akili

(Get Rating)

Akili, Inc, a digital medicine company, develops digital therapeutics for cognitive impairments. It provides EndeavorRx, a physician-prescribed video game-based treatment designed to directly target cognitive functioning. The company is based in Boston, Massachusetts.

Further Reading

The Fly logo

Receive News & Ratings for Akili Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akili and related companies with MarketBeat.com's FREE daily email newsletter.